4basebio PLC (AIM:4BB)
London · Delayed Price · Currency is GBP · Price in GBX 509.00
-53.50 (-9.51%)
Oct 15, 2026, 4:13 PM GMT
4basebio Market Cap
4basebio has a market cap or net worth of 82.35 million as of October 15, 2026. It is the 24,284th most valuable company in the world and the 532nd biggest in the United Kingdom. Its market cap has decreased by 29.99% in one year.
Market Cap
82.35M
Enterprise Value
91.41M
Revenue
781.00K
Global Rank
Country Rank
#532 United Kingdom
PE Ratio
n/a
ChartMarket Cap Chart
Since February 17, 2021, 4basebio's market cap has increased from 41.57M to 82.35M, an increase of 98.10%. That is a compound annual growth rate of 12.84%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 14, 2026 | 87.40M | -8.18% |
| Dec 31, 2025 | 95.19M | -38.57% |
| Dec 31, 2024 | 154.94M | 84.96% |
| Dec 29, 2023 | 83.77M | -4.21% |
| Dec 30, 2022 | 87.45M | 15.45% |
| Dec 31, 2021 | 75.75M | 82.22% |
| Feb 17, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Avacta Group | 311.54M |
| PureTech Health | 276.07M |
| Scancell Holdings | 113.34M |
| Bioventix | 94.57M |
| Faron Pharmaceuticals Oy | 75.59M |
| Poolbeg Pharma | 52.60M |
| Hemogenyx Pharmaceuticals | 51.34M |
| Ondine Biomedical | 50.66M |